Navigation Links
Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
Date:9/16/2008

ome technology licensed from Pevion Biotech Ltd. Mymetics' vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, a generally accepted approach coupled, uniquely and most importantly, with early events of pathogen transmission, such as preventing virus entry across the mucosal tissues, the primary entry door of most pathogens. Virosomes are lipidic vesicles derived from influenza virus membrane that are non-replicative antigen carriers which possess intrinsic systemic and mucosal adjuvant properties. Virosomes are approved in 42 countries and have been used since 1994 for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus.

For further information regarding the Company and its mucosal approach, please visit http://www.mymetics.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements."Such forward-looking statements are sometimes identified by words such as "intends,""anticipates,""believes,""expects" and "hopes."The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings
'/>"/>

SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... N.J., Feb. 3, 2011 BioNeutral Group, Inc. (OTC ... science technology-based company, today announced the formation of BioNeutral ... Inc., and the appointment of Frank Battafarano as the ... BioNeutral Services will market and distribute a ...
... 2011 A VANIR Pharmaceuticals, Inc. ... the three months ended December 31, 2010. For the ... $12.1 million, or $0.11 loss per share, compared with a net ... same period in fiscal 2010. Net revenues consisting primarily of royalty ...
Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 2AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 4AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 5AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 6
(Date:8/22/2014)... study finds a wide range of epigenetic changesalterations in ... environmental exposuresin children with Crohn,s disease (CD), reports ... Crohn,s & Colitis Foundation of America (CCFA). The ... a part of Wolters Kluwer Health . ... in several regions of the genome in children with CD, ...
(Date:8/22/2014)... Women treated for the cancer Hodgkin lymphoma will be ... after researchers estimated their risk of premature menopause with ... Journal of the National Cancer Institute , are ... women in England and Wales treated for the cancer ... Previous research has suggested that women with Hodgkin lymphoma ...
(Date:8/22/2014)... The New Jersey Institute for Food, Nutrition ... of New Jersey has joined forces with ChopChop ... young people about health and nutrition in a new ... organizations. , The partnership will encompass quarterly custom editions ... video communications. ChopChop Magazine features plenty of child-friendly ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ticket Down ... in East Hartford, CT at Rentschler Field. There has never ... the United States than right now. After the strong showing at ... fans and the sport is being featured in large stadiums around ... an eight team tournament that featured some of the best club ...
(Date:8/22/2014)... Statesville, N.C. (PRWEB) August 22, 2014 ... the managed employee reward and recognition industry, has received ... With an extraordinary growth rate of 134%, TharpeRobbins remains ... companies in North America. TharpeRobbins was previously on the ... are honored to be included in this distinguished list ...
Breaking Medicine News(10 mins):Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 2Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 3Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 2Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 3
... KUNMING, China, Sept. 13 /Xinhua-PRNewswire-FirstCall/ -- China,Shenghuo ... KUN ), which is engaged in ... nutritional supplement and cosmetic,products in the People,s ... the full-scale launch of its 12Ways(R) Chinese ...
... Sept. 13 Scimitar Equity Research, Inc.,(Scimitar) today ... Bulletin,Board: ABOS) entitled: "Enhancing the Recovery of Patients ... research review is,available on Scimitar,s website: http://www.scimitarequity.com ... Device The SEPET(TM) Liver Assist Device is ...
... correlation, with risk doubling as blood cells decline , ... declining blood platelet counts may be at increased risk ... behavioral and motor skill problems, researchers report. , Researchers ... Johns Hopkins University School of Medicine in Baltimore studied ...
... (Sept. 10, 2007) -- For high-blood-pressure patients, preventing or ... risk of heart failure. The study is published in ... by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in ... all high-blood-pressure patients, or 12 million Americans, have LVH ...
... Health Corp. is the Distributor of the Popular Dietary Supplement ... ... Health Corp. is proud to,announce its retail presence has expanded again ... and Sweet Bay,Supermarkets. LipidShield Plus is the popular NATURAL breakthrough ...
... Reports Solid Progress on Child Survival, NEW YORK, Sept. ... below 10 million per year to 9.7 million,down from almost ... an historic moment," said UNICEF Executive Director Ann M.,Veneman. "Now ... for the,achievement of the Millennium Development Goals." Among these ...
Cached Medicine News:Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 3Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 4Health News:Arbios Systems, Inc's Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc. 2Health News:Falling Platelet Counts May Signal HIV-Linked Dementia 2Health News:Preventing or reducing enlarged heart decreases risk of heart failure 2Health News:New Health Corp. Announces the Addition of Hannaford Bros., Kash N Karry and Sweet Bay Supermarkets to its Retail Outlets 2Health News:Child Deaths Fall Below 10 Million For First Time 2Health News:Child Deaths Fall Below 10 Million For First Time 3Health News:Child Deaths Fall Below 10 Million For First Time 4
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
Medicine Products: